Contact
Please use this form to send email to PR contact of this press release:
Genmab Announces Preliminary Cervical Cancer Data from Tisotumab Vedotin Phase I/II Study
TO:
Please use this form to send email to PR contact of this press release:
Genmab Announces Preliminary Cervical Cancer Data from Tisotumab Vedotin Phase I/II Study
TO: